BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 23700057)

  • 1. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
    Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
    Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
    Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
    Koehler R; Bartram CR
    Klin Padiatr; 2013 May; 225 Suppl 1():S40-4. PubMed ID: 23700054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes simplex virus reactivation and disease during treatment for childhood acute lymphoblastic leukemia.
    Lauten M; Güttel C; Härtel C; Erdlenbruch B
    Klin Padiatr; 2014 May; 226(3):188-9. PubMed ID: 24158893
    [No Abstract]   [Full Text] [Related]  

  • 8. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
    Pillon M; Aricò M; Basso G; Locatelli F; Citterio M; Micalizzi C; Testi AM; Barisone E; Nardi M; Lombardi A; Rondelli R; Rosolen A;
    Pediatr Blood Cancer; 2011 Apr; 56(4):544-50. PubMed ID: 21298738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
    Glodkowska E; Bialas A; Jackowska T
    Med Wieku Rozwoj; 2007; 11(2 Pt 1):153-8. PubMed ID: 17625285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity].
    Karachunskiĭ AI; Miakova NV; Rumiantseva IuV; Timakov AM; Makhortykh TZh; Fechina LG; Shamardina AV; Dudkin SA; Lebedev VV; Varfolomeeva SR; Timofeeva VN; Herold R; Stakelberg A; Henze G; Rumiantsev AG
    Ter Arkh; 2007; 79(7):19-26. PubMed ID: 17802785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
    Biondi A; Rizzari C; Valsecchi MG; De Lorenzo P; Aricò M; Basso G; Locatelli F; Lo Nigro L; De Rossi G; Masera G
    Haematologica; 2006 Apr; 91(4):534-7. PubMed ID: 16537119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia.
    Ziino O; Russo D; Orlando MA; Benigno V; Locatelli F; Aricò M
    Med Pediatr Oncol; 2002 Jul; 39(1):32-4. PubMed ID: 12116076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visualization of Vertebral Body Deformities in Childhood by MRI in a Boy with ALL.
    Zhang XD; Madjidyar J; Peters S
    Rofo; 2019 Aug; 191(8):752-753. PubMed ID: 30900230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 42.